Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

Nature Biotechnology

Volumn 24, Issue 12, 2006, Pages 1591-1597

  Cox, Kevin M ^a   Sterling, Jason D ^a   Regan, Jeffrey T ^a   Gasdaska, John R ^a   Frantz, Karen K ^a   Peele, Charles G ^a   Black, Amelia ^b   Passmore, David ^b   Moldovan Loomis, Cristina ^b   Srinivasan, Mohan ^b   Cuison, Severino ^b   Cardarelli, Pina M ^b   Dickey, Lynn F ^a  

^a Biolex Therapeutics   (United States)

^b Medarex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BIODIVERSITY; CELLS; DRUG THERAPY; PLANTS (BOTANY); PROTEINS;

GLYCAN OPTIMIZATION; HUMAN MONOCLONAL ANTIBODY; THERAPEUTIC PROTEINS; ZOONOTIC PATHOGENS;

BIOTECHNOLOGY;

ALPHA 1,3 FUCOSYLTRANSFERASE; BETA 1,2 XYLOSYLTRANSFERASE; CD30 ANTIGEN; CELL RECEPTOR; GLYCAN; HUMAN MONOCLONAL ANTIBODY; TRANSFERASE;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CHO CELL; CONTROLLED STUDY; EFFECTOR CELL; LEMNA MINOR; NONHUMAN; NUCLEOTIDE SEQUENCE; PLANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN TARGETING; RECEPTOR BINDING; RNA INTERFERENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; ARACEAE; BIOTECHNOLOGY; CHO CELLS; CRICETINAE; CRICETULUS; GLYCOSYLATION; HUMANS; PLANTS, GENETICALLY MODIFIED; POLYSACCHARIDES; PROTEIN BIOSYNTHESIS; RECOMBINANT PROTEINS; RNA INTERFERENCE;

CRICETULUS GRISEUS; LEMNA MINOR;

EID: 33845711353     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1260     Document Type: Article

References (30)

1. Gasdaska, J., Spencer, D. & Dickey, L. Advantages of therapeutic protein production in the aquatic plant Lemna. Bioprocessing J. 3, 50-56 (2003).
2. Krapp, S., Mimura, Y., Jefferis, R., Huber, R. & Sondermann, P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325, 979-989 (2003).
3. Shinkawa, T. et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278, 3466-3473 (2003).
4. Shields, R.L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733-26740 (2002).
5. Wright, A. & Morrison, S. Effect of glycosylation on antibody function: Implications for genetic engineering. Trends Biotechnol. 15, 26-32 (1997).
6. Hiatt, A., Cafferkey, R. & Bowdish, K. Production of antibodies in transgenic plants. Nature 342, 76-78 (1989).
7. Bakker, H. et al. An antibody produced in tobacco expressing a hybrid β-1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes. Proc. Natl. Acad. Sci. USA 103, 7577-7582 (2006).
8. Triguero, A. et al. Plant-derived mouse IgG monoclonal antibody fused to KDEL endoplasmic reticulum-retention signal is N-glycosylated homogeneously throughout the plant with mostly high-mannose-type N-glycans. Plant Biotechnol. J. 3, 449-457 (2005).
9. Bardor, M. et al. Monoclonal C5-1 antibody produced in transgenic alfalfa plants exhibits a N-glycosylation that is homogenous and suitable for glyco-engineering into human-compatible structures. Plant Biotechnol. J. 1, 451-462 (2003).
10. Gomord, V., Chamberlain, P., Jefferis, R. & Faye, L. Biopharmaceutical production in plants: Problems, solutions and opportunities. Trends Biotechnol. 23, 559-565 (2005).
11. Zeitlin, L. et al. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat. Biotechnol. 16, 1361-1364 (1998).
12. Ma, J.K. et al. Characterization of a recombinant plant monoclonal secretory antibody and preventative immunotherapy in humans. Nat. Med. 4, 601-606 (1998).
13. Bencurova, M., Hemmer, W., Focke-Tejkl, M., Wilson, I. & Altmann, F. Specificity of IgG and IgE antibodies against plant and insect glycoprotein glycans determined with artificial glycoforms of human transferrin. Glycobiology 14, 457-466 (2004).
14. Yamamoto, Y. et al. Genetic transformation of duckweed Lemna gibba and Lemna minor. In Vitro Cell. Dev. Biol. 37, 349-353 (2001).
15. Borchmann, P. et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 102, 3737-3742 (2003).
16. Zhu, L. et al. Production of human monoclonal antibody in eggs of chimeric chickens. Nat. Biotechnol. 23, 1159-1169 (2005).
17. Elbers, I.J. et al. Influence of growth conditions and developmental stage on N-glycan heterogeneity of transgenic immunoglobulin G and endogenous proteins in tobacco leaves. Plant Physiol. 126, 1314-1322 (2001).
18. Fujiyama, K. et al. N-linked glycan structures of a mouse monoclonal antibody produced from tobacco BY2 suspension-cultured cells. J. Biosci. Bioeng. 101, 212-218 (2006).
19. Koprivova, A. et al. N-glycosylation in the moss Physcomitrella patens is organized similarly to that in higher plants. Plant Biol. 5, 582-591 (2003).
20. Kanda, Y. et al. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol. Bioeng. 94, 680-688 (2006).
21. Cartron, G. et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99, 754-758 (2002).
22. Weng, W.K. & Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21, 3940-3947 (2003).
23. Weng, W.K., Czerwinski, D., Timmerman, J., Hsu, F. & Levy, R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22, 4717-4724 (2004).
24. Niwa, R. et al. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcγRIIIa functional polymorphism. Clin. Cancer Res. 10, 6248-6255 (2004).
25. Urlaub, G. et al. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. Somat. Cell Mol. Genet. 12, 555-566 (1986).
26. Hepburn, A.G. et al. The use of pNJ5000 as an intermediate vector for the genetic manipulation of Agrobacterium Ti-plasmids. J. Gen. Microbiol. 131, 2961-2969 (1985).
27. Schenk, R. & Hildenbrandt, A. Medium and techniques for induction and growth of monocotyledonous and dictoyledonous plant cell cultures. Can. J. Bot. 50, 199-204 (1972).
28. Leiter, H. et al. Purification, cDNA cloning, and expression of GDP-L-Fuc:Asn-linked GlcNAc α-1,3-fucosyltransferase from mung beans. J. Biol. Chem. 274, 21830-21839 (1999).
29. Packer, N., Lawson, M., Jardine, D. & Redmond, J. A general approach to desalting oligosaccharides released from glycoproteins. Glycoconj. J. 49, 737-747 (1998).
30. Anumula, K.R. & Dhume, S. High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acid. Glycobiology 8, 685-694 (1998).